New! Sign up for our free email newsletter.
Science News
from research organizations

Drug that targets scar-like tissue in tumors shows promise for aggressive pancreatic cancer

Date:
August 29, 2023
Source:
Garvan Institute of Medical Research
Summary:
Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of pancreatic ductal adenocarcinomas.
Share:
FULL STORY

Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like 'fibrotic' tissue within tumours shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10%.

The research in mouse models showed that when given in combination with chemotherapy, the drug PXS-5505 increased survival time by more than 35%, compared to chemotherapy treatment alone.

"The preclinical validation of this first-in-class anti-fibrotic drug marks a major milestone in our quest to overcome the significant challenges in treating pancreatic cancer and brings hope to patients and their families," says Associate Professor Thomas Cox, head of the Matrix & Metastasis Lab at Garvan and senior author of the study, published in the journal Nature Cancer.

Potential to increase cancer survival

Pancreatic cancer is often diagnosed at an advanced stage, which means that chemotherapy is often the only treatment option available. Many pancreatic cancers develop chemotherapy resistance soon after treatment starts, which contributes to the poor survival of patients. Part of this resistance is driven by tumour fibrosis -- the formation of a mesh of scar tissue-like collagen -- within and around pancreatic tumours that in turn reduces the effectiveness of chemotherapy drugs.

The new drug PXS-5505, developed by Sydney-based pharmaceutical research company Pharmaxis (ASX: PXS) and currently in Phase II clinical trials for the treatment of bone marrow cancer, works by blocking a family of enzymes that are critical for the deposition of collagen into the fibrotic tissue around tumours.

In collaboration with Pharmaxis, Garvan researchers found that the drug significantly reduced fibrosis in pancreatic tumours in mouse models.

The combination therapy also substantially reduced the spread of the cancer to other organs, such as the liver, by 45%.

"PXS-5505 returns the tumour microenvironment to a more 'normal' state by reducing fibrosis and decreasing tumour stiffness," explains Dr Jessica Chitty, Senior Research Officer at Garvan and first author of the study. "This allows chemotherapy drugs to penetrate the tumours more easily, work more effectively, and destroy more cancer cells."

"PXS-5505 shows real potential to improve chemotherapy for patients," says Associate Professor Cox. "We are now in the process of progressing this work toward clinical trials that will evaluate this promising drug combination approach for pancreatic cancer patients."

"Pharmaxis has already seen very promising early results in a Phase II trial with patients that have the bone marrow cancer myelofibrosis," commented Gary Phillips, CEO of Pharmaxis. "This groundbreaking research stems from a long collaboration with the team of high calibre researchers at the Garvan Institute and provides exciting new evidence that PXS-5505 may also have a role as a therapy to improve the effect of current chemotherapy drugs in solid tumours like pancreatic cancer and extending the life of patients."


Story Source:

Materials provided by Garvan Institute of Medical Research. Note: Content may be edited for style and length.


Journal Reference:

  1. Jessica L. Chitty, Michelle Yam, Lara Perryman, Amelia L. Parker, Joanna N. Skhinas, Yordanos F. I. Setargew, Ellie T. Y. Mok, Emmi Tran, Rhiannon D. Grant, Sharissa L. Latham, Brooke A. Pereira, Shona C. Ritchie, Kendelle J. Murphy, Michael Trpceski, Alison D. Findlay, Pauline Melenec, Elysse C. Filipe, Audrey Nadalini, Sipiththa Velayuthar, Gretel Major, Kaitlin Wyllie, Michael Papanicolaou, Shivanjali Ratnaseelan, Phoebe A. Phillips, George Sharbeen, Janet Youkhana, Alice Russo, Antonia Blackwell, Jordan F. Hastings, Morghan C. Lucas, Cecilia R. Chambers, Daniel A. Reed, Janett Stoehr, Claire Vennin, Ruth Pidsley, Anaiis Zaratzian, Andrew M. Da Silva, Michael Tayao, Brett Charlton, David Herrmann, Max Nobis, Susan J. Clark, Andrew V. Biankin, Amber L. Johns, David R. Croucher, Adnan Nagrial, Anthony J. Gill, Sean M. Grimmond, Lorraine A. Chantrill, Angela Chou, Tanya Dwarte, Xanthe L. Metcalf, Gloria Jeong, Lara Kenyon, Nicola Waddell, John V. Pearson, Ann-Marie Patch, Katia Nones, Felicity Newell, Pamela Mukhopadhyay, Venkateswar Addala, Stephen Kazakoff, Oliver Holmes, Conrad Leonard, Scott Wood, Oliver Hofmann, Jaswinder S. Samra, Nick Pavlakis, Jennifer Arena, Hilda A. High, Ray Asghari, Neil D. Merrett, Amitabha Das, Peter H. Cosman, Kasim Ismail, Alina Stoita, David Williams, Allan Spigellman, Duncan McLeo, Judy Kirk, James G. Kench, Peter Grimison, Charbel Sandroussi, Annabel Goodwin, R. Scott Mead, Katherine Tucker, Lesley Andrews, Michael Texler, Cindy Forrest, Mo Ballal, David Fletcher, Maria Beilin, Kynan Feeney, Krishna Epari, Sanjay Mukhedkar, Nikolajs Zeps, Nan Q. Nguyen, Andrew R. Ruszkiewicz, Chris Worthley, John Chen, Mark E. Brooke-Smith, Virginia Papangelis, Andrew D. Clouston, Andrew P. Barbour, Thomas J. O’Rourke, Jonathan W. Fawcett, Kellee Slater, Michael Hatzifotis, Peter Hodgkinson, Mehrdad Nikfarjam, James R. Eshleman, Ralph H. Hruban, Christopher L. Wolfgang, Aldo Scarpa, Rita T. Lawlor, Vincenzo Corbo, Claudio Bassi, Nigel B. Jamieson, David K. Chang, Stephan B. Dreyer, Lea Abdulkhalek, Tatjana Schmitz, Victoria Lee, Kym Pham Stewart, Mehreen Arshi, Angela M. Steinmann, Marina Pajic, Paul Timpson, Wolfgang Jarolimek, Thomas R. Cox. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nature Cancer, 2023; DOI: 10.1038/s43018-023-00614-y

Cite This Page:

Garvan Institute of Medical Research. "Drug that targets scar-like tissue in tumors shows promise for aggressive pancreatic cancer." ScienceDaily. ScienceDaily, 29 August 2023. <www.sciencedaily.com/releases/2023/08/230829125932.htm>.
Garvan Institute of Medical Research. (2023, August 29). Drug that targets scar-like tissue in tumors shows promise for aggressive pancreatic cancer. ScienceDaily. Retrieved October 31, 2024 from www.sciencedaily.com/releases/2023/08/230829125932.htm
Garvan Institute of Medical Research. "Drug that targets scar-like tissue in tumors shows promise for aggressive pancreatic cancer." ScienceDaily. www.sciencedaily.com/releases/2023/08/230829125932.htm (accessed October 31, 2024).

Explore More

from ScienceDaily

RELATED STORIES